Cargando…
Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible
Substantial reductions in breast cancer incidence in women 50 years old or older have been observed recently in many developed countries, and falling use of menopausal hormone therapy (HT) remains the most plausible explanation. In keeping with recent observations from the Women's Health Initia...
Autores principales: | Banks, Emily, Canfell, Karen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880418/ https://www.ncbi.nlm.nih.gov/pubmed/20236464 http://dx.doi.org/10.1186/bcr2463 |
Ejemplares similares
-
Menopausal hormone therapy: Characterising users in an Australian national cross-sectional study
por: Velentzis, Louiza S., et al.
Publicado: (2021) -
Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study
por: Salagame, Usha, et al.
Publicado: (2018) -
Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study
por: Velentzis, Louiza S., et al.
Publicado: (2016) -
Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations
por: Velentzis, Louiza S., et al.
Publicado: (2017) -
Accurate categorisation of menopausal status for research studies: a step-by-step guide and detailed algorithm considering age, self-reported menopause and factors potentially masking the occurrence of menopause
por: Yap, Sarsha, et al.
Publicado: (2022)